Ginkgo Bioworks Holdings, Inc. (DNA)

USD 8.79

(-8.53%)

EBITDA Summary of Ginkgo Bioworks Holdings, Inc.

  • Ginkgo Bioworks Holdings, Inc.'s latest annual EBITDA in 2023 was -821.29 Million USD , up 72.45% from previous year.
  • Ginkgo Bioworks Holdings, Inc.'s latest quarterly EBITDA in 2024 Q1 was -145.86 Million USD , up 38.64% from previous quarter.
  • Ginkgo Bioworks Holdings, Inc. reported an annual EBITDA of -2.05 Billion USD in 2022, down -16.13% from previous year.
  • Ginkgo Bioworks Holdings, Inc. reported an annual EBITDA of -1.8 Billion USD in 2021, down -1646.33% from previous year.
  • Ginkgo Bioworks Holdings, Inc. reported a quarterly EBITDA of -133.19 Million USD for 2024 Q2, up 17.07% from previous quarter.
  • Ginkgo Bioworks Holdings, Inc. reported a quarterly EBITDA of -39.04 Million USD for 2023 Q3, up 75.49% from previous quarter.

Annual EBITDA Chart of Ginkgo Bioworks Holdings, Inc. (2023 - 2001)

Historical Annual EBITDA of Ginkgo Bioworks Holdings, Inc. (2023 - 2001)

Year EBITDA EBITDA Growth
2023 -821.29 Million USD 72.45%
2022 -2.05 Billion USD -16.13%
2021 -1.8 Billion USD -1646.33%
2020 -108.58 Million USD -32.66%
2019 -106.65 Million USD 0.0%
2001 -219.71 Million USD 0.0%

Peer EBITDA Comparison of Ginkgo Bioworks Holdings, Inc.

Name EBITDA EBITDA Difference
ADC Therapeutics SA -146.76 Million USD -459.609%
Alto Neuroscience, Inc. -34.56 Million USD -2276.289%
Annovis Bio, Inc. -45.03 Million USD -1723.677%
Biohaven Pharmaceutical Holding Company Ltd. -429.13 Million USD -91.382%
Nuvation Bio Inc. -99.6 Million USD -724.591%
Nuvation Bio Inc. -99.6 Million USD -724.591%
Arcus Biosciences, Inc. -283 Million USD -190.21%
Theriva Biologics, Inc. -19.85 Million USD -4036.663%
Zymeworks Inc. -129.95 Million USD -531.978%